Monocarboxylate Transporter 8 (MCT8) Deficiency

Monocarboxylate transporter 8 deficiency is also called Allan-Herndon-Dudley syndrome (AHDS), SLC16A2-related disorder, X-linked intellectual disability–hypotonia syndrome, and thyroid hormone transporter MCT8 deficiency. It is X-linked, which means it mainly affects boys, while girls (carriers) are often healthy or only mildly affected, but some females can have symptoms if X-inactivation is unfavorable. NCBI+2MedlinePlus+2

MCT8 deficiency is a genetic condition. A change (variant) in a gene called SLC16A2 stops the body from making a normal MCT8 protein. This protein is a “transporter” that moves the active thyroid hormone T3 into brain cells and some other cells. Without working MCT8, T3 cannot enter the brain well. The brain becomes functionally low in thyroid hormone (cerebral hypothyroidism) while the rest of the body has too much T3 (peripheral thyrotoxicosis). This mix causes severe motor and cognitive delay, weak muscle tone in infancy that later becomes stiffness/spasticity, feeding problems, poor weight gain, and movement disorders. Typical blood tests show high T3, low T4, low reverse T3, and TSH that is normal to slightly high; brain MRI often shows delayed myelination. Frontiers+3PMC+3PMC+3

Monocarboxylate transporter 8 deficiency is a rare, mostly male, genetic condition that affects how the brain receives thyroid hormone. The MCT8 protein sits in the cell membrane and acts like a “doorway” that lets thyroid hormones—especially T3—enter nerve cells. If this doorway is broken or missing because of a change (variant) in the SLC16A2 gene (the gene that makes MCT8), the brain does not get enough T3 during development. As a result, babies develop low muscle tone, severe delays in moving and speaking, and later often develop stiff muscles and abnormal movements. Blood tests show a special “fingerprint”: T3 is high, T4 is low or low-normal, reverse T3 is low, and TSH is normal or only slightly high. Doctors diagnose it by finding a disease-causing variant in SLC16A2. NCBI+2PMC+2

Even though the body has high T3 in the blood, the brain cannot bring T3 inside the cells. So the brain is functionally hypothyroid, while the rest of the body can look hyperthyroid (fast heart rate, poor weight gain). The lack of T3 in the developing brain also delays myelination (the “insulation” on nerve fibers), which you can often see on MRI scans. Frontiers+1

Other names

• Allan–Herndon–Dudley syndrome (AHDS)

• SLC16A2-related MCT8 deficiency

• MCT8-specific thyroid hormone cell transporter deficiency

• X-linked intellectual disability with movement disorder due to MCT8

These names all describe the same disorder, just from different angles (gene name, protein name, or main clinical features). Orpha+1

• The brain needs thyroid hormone, especially T3, to build and wire nerve circuits.

• MCT8 is a transport protein that moves T3 (and T4) from the blood into brain cells.

• When MCT8 is missing or faulty, T3 cannot get into neurons. The brain becomes low in T3 even though the blood may have too much T3.

• This mismatch leads to severe developmental problems and a characteristic thyroid test pattern. MRI scans often show delayed myelin in young children. Frontiers+1

Types

There is one underlying cause—variants in SLC16A2—but the severity can vary. It’s helpful to think about “types” as clinical patterns rather than official categories:

1. Classic infantile form. Boys present in the first months with very poor head control, low tone, feeding difficulty, and later severe motor and speech delay. Thyroid “fingerprint” is typical (high T3, low T4, low rT3, normal/low-normal TSH). NCBI

2. Intermediate/milder spectrum. Some boys sit with support or speak a few words, or have less severe movement problems. This reflects different variants and other biological modifiers. PubMed

3. Female carriers with symptoms. Most female carriers are healthy because they have a second normal X chromosome, but some have skewed X-inactivation and may show mild learning or movement issues. NCBI

4. Adult survivors/late-diagnosed individuals. A small number are diagnosed later in life with severe motor disability and the same thyroid pattern. NCBI

(Researchers emphasize that this is a spectrum, not rigid subtypes.) PubMed

Causes

Note: The fundamental cause is a disease-causing variant in SLC16A2. Below are the ways that cause can appear or act in the body. I’m listing them separately so each mechanism is clear.

1. Missense variants changing one amino acid so MCT8 loses its transport function. This is common and can severely reduce T3 transport into neurons. PMC

2. Nonsense variants that create a “stop” signal and truncate the protein so it cannot work. NCBI

3. Frameshift variants that disrupt the reading frame, producing a nonfunctional protein. NCBI

4. Splice-site variants that alter how the gene’s message is pieced together, yielding an abnormal or unstable protein. NCBI

5. Whole-gene deletions or larger X-chromosome rearrangements that remove SLC16A2 entirely. Orpha

6. Promoter or regulatory variants that reduce how much MCT8 is made, lowering transport capacity. (Documented in genetic series.) NCBI

7. De novo variants (new in the child, not present in either parent). These explain some sporadic cases. NCBI

8. X-linked inheritance from a carrier mother—the most common route in families. Genetic Diseases Information Center

9. Skewed X-inactivation in females, which can unmask symptoms in carriers and modify severity in rare affected females. NCBI

10. Mosaicism in a parent, where only some cells carry the variant, which can lead to recurrence in a family even if routine parental testing looks negative. NCBI

11. A variant that disrupts the T3-binding region of MCT8, blocking hormone transport despite a full-length protein. PMC

12. A variant that traps MCT8 inside the cell (mislocalization), so it never reaches the membrane “doorway.” PMC

13. Loss of interaction with helper molecules needed for proper membrane insertion or stability, reducing effective transport. (Mechanism described in transporter biology.) PMC

14. Copy-number changes within SLC16A2 that alter critical exons without deleting the whole gene. Orpha

15. Complex or multi-exon deletions/duplications disrupting the protein’s transmembrane segments. Orpha

16. Gene conversion or recombination events affecting SLC16A2 structure. (Rare mechanisms included in broad genetic diagnostics.) Orpha

17. Uniparental disomy of X (extremely rare), which could fix a variant across tissues in a female. (General X-linked genetics principle; considered in difficult pedigrees.) NCBI

18. Modifier biology in thyroid hormone pathway (for example, deiodinase activity), which may shape the blood hormone pattern and clinical severity even with the same SLC16A2 variant. Frontiers

19. Population founder variants in some families or regions, leading to repeated cases with the same change. (Reported in cohort papers.) PubMed

20. Consanguinity or small gene pools that increase the chance a rare variant is passed on, raising recurrence risk in some communities. (General inheritance risk factor acknowledged in rare X-linked conditions.) NCBI

Symptoms

1. Global developmental delay. Babies are late to hold the head, sit, stand, or walk; many never walk. This is the most visible feature. Genetic Diseases Information Center

2. Low muscle tone (hypotonia) in infancy. The baby feels “floppy,” with poor head control and weak trunk. American Thyroid Association

3. Feeding difficulty and poor weight gain. Weak oromotor control and high energy use can lead to failure to thrive. Children’s Hospital of Philadelphia

4. Fast heart rate and warm skin in some children. This reflects the high T3 effect in the body. American Thyroid Association

5. Spasticity and hyperreflexia later in childhood. Muscles become stiff and reflexes brisk over time. American Thyroid Association

6. Abnormal movements (dystonia, choreoathetoid movements). These are involuntary or twisting movements. Orpha

7. Severe speech delay or absent speech. Many children understand more than they can express. Genetic Diseases Information Center

8. Intellectual disability (moderate to severe). Learning is greatly affected. Genetic Diseases Information Center

9. Contractures and scoliosis from long-standing motor problems. Orpha

10. Swallowing problems and aspiration, which can cause coughing with feeds and chest infections. Orpha

11. Constipation or reflux due to low tone and neurologic dysfunction. Orpha

12. Sleep disturbance and irritability, sometimes linked to discomfort from spasticity or reflux. Orpha

13. Thermoregulation issues (sweating or heat intolerance) in some children, reflecting peripheral thyroid effects. Orpha

14. Seizures (not universal). Some children develop seizures; others do not. Orpha

15. Slow or abnormal myelination on MRI, which mirrors the brain’s thyroid hormone shortage. Frontiers

Diagnostic tests

A) Physical examination

1. General growth and nutrition check. The clinician measures weight, length/height, and head size, and looks for signs of poor feeding, under-nutrition, or dehydration. These findings support the overall picture but are not specific to MCT8 deficiency. Children’s Hospital of Philadelphia

2. Neuromotor exam for tone and posture. Low tone (hypotonia) in infants, later evolving to stiffness (spasticity) and brisk reflexes, is a common pattern in this condition. American Thyroid Association

3. Oral-motor and swallow assessment. The clinician watches feeding, checks gag and cough, and looks for choking or aspiration risk. This helps guide feeding safety plans. Orpha

4. Cardiovascular check (heart rate, rhythm). Because T3 is often high in the body, some children have fast heart rates; this exam picks up those signs. American Thyroid Association

B) Manual developmental and functional tests

5. Hammersmith Infant Neurological Examination (HINE) or similar standardized neuro exam. This structured bedside test scores tone, posture, and reflexes to track change over time.

6. Bayley Scales (or equivalent developmental testing). These measure cognitive, language, and motor skills, giving an objective baseline and follow-up for the child’s development.

7. Gross Motor Function Classification System (GMFCS)/Gross Motor Function Measure (GMFM). These tools describe and track motor abilities and needs for support devices over time.

(These tools are standard pediatric neurology/rehab measures used across many neurodevelopmental disorders.)

C) Laboratory and pathological tests

8. Thyroid panel: free T3, free T4, TSH. In MCT8 deficiency, free T3 is high, free T4 is low or low-normal, and TSH is normal to slightly high—a very helpful “fingerprint.” Children’s Hospital of Philadelphia+1

9. Reverse T3 (rT3). rT3 is usually low in this condition and helps differentiate it from other thyroid problems. NCBI

10. Free T3/free T4 ratio. Some centers use a high FT3/FT4 ratio threshold to flag possible MCT8 deficiency and prompt genetic testing. e-apem.org

11. Sex hormone–binding globulin (SHBG). SHBG can be elevated by high T3 and may support the picture of peripheral thyrotoxicosis. (Used as a supportive marker in endocrine practice.) American Thyroid Association

12. Liver enzymes and creatine kinase (CK). These may be mildly abnormal and help screen overall health and medication safety before therapies. (Supportive, not diagnostic.)

13. Molecular testing of SLC16A2 (sequencing). This is the definitive test that confirms the diagnosis by finding a pathogenic variant. NCBI

14. Deletion/duplication analysis (e.g., MLPA or chromosomal microarray focused on the gene) to detect larger missing or extra pieces not seen on sequencing. Orpha

D) Electrodiagnostic tests

15. EEG (electroencephalogram). If seizures are suspected, EEG looks for epileptic activity and helps guide anti-seizure treatment. (Findings vary; not specific to MCT8 deficiency.)

16. EMG and nerve conduction studies in selected cases. These can help exclude a primary muscle or nerve disease when tone is very low early on. (Usually normal or nonspecific in MCT8 deficiency.)

17. Evoked potentials (visual or auditory). These look at how the brain’s pathways conduct signals and can reflect myelination status; they are supportive tests.

E) Imaging tests

18. Brain MRI. Often shows delayed or abnormal myelination (especially under age five) and sometimes cerebral atrophy. In some children, myelination slowly improves over time, but early delay is common. Frontiers+1

19. MR spectroscopy. Can show metabolic patterns that support poor myelination and global brain changes in this disorder. Oxford Academic

20. Videofluoroscopic swallow study (or fiberoptic endoscopic evaluation). If aspiration is suspected, this imaging test shows whether food or liquid goes into the airway. It guides safe feeding strategies.

Non-pharmacological treatments (therapies and others)

Important note: These are supportive. They do not fix the transporter, but they reduce complications and improve comfort and function.

1. Early physical therapy: daily, gentle positioning, facilitation of head/trunk control; prevents contractures and improves circulation.

2. Occupational therapy: seating, transfers, self-care adaptations; improves participation and reduces caregiver strain.

3. Speech/feeding therapy: safe swallowing, pacing, thickening strategies; lowers aspiration risk and improves nutrition.

4. Nutritional support plan: calorie-dense feeds, reflux precautions, hydration; supports growth and bone health.

5. Posture and seating systems: custom chairs, head/torso supports; prevent scoliosis progression and pressure sores.

6. Orthotics and splinting: AFOs/wrist splints; maintain joint position and aid standing programs.

7. Serial casting/stretching programs: short cycles to lengthen tight muscles; delays need for surgery.

8. Hydrotherapy: buoyancy reduces spasm and allows practice of movements in water.

9. Respiratory care: airway clearance, cough-assist, chest physiotherapy; reduces infection risk in weak cough or aspiration.

10. Sleep hygiene routines: fixed schedules, quiet/dim environment; supports behavior and caregiver rest.

11. Behavioral support and routines: predictable daily plans reduce distress.

12. Assistive communication (AAC): eye-gaze boards, switches, or speech-generating devices; improves interaction and learning.

13. Vision and hearing support: glasses, auditory aids; maximizes remaining sensory input.

14. Dental care plan: fluoride varnish, safe positioning in the chair; lowers decay and aspiration risk.

15. Skin care and pressure relief: cushions, frequent turns; prevents ulcers.

16. Hip surveillance program: regular exams and X-rays; early detection reduces pain and complex surgery later.

17. Bone health measures: supported standing frame, weight-bearing, vitamin D/calcium (as needed); reduces osteoporosis risk.

18. Caregiver training: safe transfers, feeding, suctioning when needed; reduces emergency events.

19. Palliative/supportive care involvement: symptom control, goals-of-care planning; improves quality of life for family.

20. Genetic counseling: explains inheritance, offers options for future pregnancies. (Clinical value and diagnostic “fingerprint” are addressed in current reviews and guidelines.) PMC+1

---

Drug treatments

Safety first: Doses below are typical examples from studies or common practice and must be individualized by a specialist (pediatric endocrinologist/neurologist). Children vary; monitoring is essential.

Targeted disease-directed therapy

1. TRIAC (tiratricol; Emcitate®) – purpose: lower high T3 in the body and partially correct the hormone imbalance; may help growth, heart rate, and metabolic markers; early treatment may support neurodevelopmental outcomes. Mechanism: thyroid hormone analog that can enter cells without MCT8 and suppresses excess T3 signaling peripherally; limited brain penetration. Example dosing used in trials: weight-based starts or fixed escalations (e.g., 175–350 μg/day start, titrating by 175–350 μg steps toward a target T3 range; median maintenance around ~39 μg/kg/day in cohorts). Key side effects: potential over- or under-treatment of thyroid state; lab cross-reactivity with FT3 assays; needs careful ECG/heart, weight, and lab monitoring. Regulatory status: EMA recommended EU authorization (Dec 2024) for peripheral thyrotoxicosis in MCT8 deficiency; ETA 2024 guidelines recommend TRIAC as long-term therapy for all MCT8 patients. PMC+5The Lancet+5Oxford Academic+5

Supportive symptom-targeted medicines (not disease-modifying, but commonly needed)

2. Propranolol (beta-blocker) – purpose: control tachycardia/tremor from peripheral thyrotoxicosis; mechanism: blocks β-adrenergic effects of excess T3; notes: watch for low BP/low HR, wheeze.

3. Clonidine/guanfacine – calm sympathetic overactivity and help sleep; notes: sedation and low BP possible.

4. Proton-pump inhibitor (e.g., omeprazole) – reduce reflux/aspiration risk; mechanism: lowers stomach acid; notes: long-term use needs review (bone/microbiome).

5. H2 blocker (e.g., famotidine) – reflux aid when PPI not suitable; notes: tolerance can develop.

6. Prokinetic (e.g., erythromycin low-dose, specialist use) – improve gastric emptying; notes: QT risk/diarrhea.

7. Laxatives (PEG/macrogol) – treat constipation; notes: titrate to soft daily stool.

8. Glycopyrrolate – reduce drooling/aspiration; notes: dry mouth, constipation.

9. Botulinum toxin injections – focal spasticity or sialorrhea; notes: localized weakness; repeat every 3–4 months.

10. Baclofen (oral) – reduce spasticity; notes: sedation, hypotonia; taper if stopping.

11. Tizanidine – alternative antispasticity; notes: sedation, liver tests.

12. Diazepam (night doses) – spasm relief; notes: sedation, dependence with long use.

13. Intrathecal baclofen (pump; see “surgeries”) – for severe generalized spasticity; notes: surgical device; overdose/withdrawal risks if pump fails.

14. Antiseizure medicines (e.g., levetiracetam, valproate, others as indicated) – for patients with seizures; notes: tailored to seizure type and comorbidities.

15. Bisphosphonates (specialist use) – for painful fractures/osteoporosis; notes: dental precautions.

16. Vitamin D and calcium (if deficient) – bone health support; notes: lab-guided dosing.

17. Iron (if iron deficiency) – improves anemia and feeding stamina; notes: causes constipation sometimes.

18. Vaccinations (per schedule) – reduce infection risk; notes: coordination with pediatrician.

19. Pain/spasm rescue (e.g., acetaminophen/ibuprofen as appropriate) – comfort during illness/therapy; notes: dosing by weight; check kidneys/liver.

20. Acid-thickening agents for feeds (as directed) – reduce aspiration in reflux; notes: choose products appropriate for age.

(Overall management goal is to restore adequate hormone signaling and treat peripheral thyrotoxicosis, while supporting neurodevelopment and preventing complications; see modern reviews and trials.) PMC+1

---

Dietary molecular supplements

Important: No supplement is proven to correct the transporter problem or change long-term neurological outcomes. Use them only to support general health, and only with the care team.

1. Vitamin D3 (dose based on labs/age) – bone mineralization support.

2. Calcium (diet first; supplement if low intake) – bone strength.

3. Omega-3 (DHA/EPA) – general neuro-nutritional support; can help with reflux sensitivity in some.

4. Multivitamin – fills small dietary gaps; avoid high iodine products.

5. Iron (if deficient) – improves energy and immunity.

6. Zinc (if low) – supports growth and immunity.

7. Probiotics – may help constipation and reflux symptoms in some.

8. Soluble fiber (e.g., inulin/psyllium, age-appropriate) – stool softening.

9. Carnitine (if low) – supports energy pathways; check levels first.

10. Protein/calorie modulars – add calories to feeds without volume.

(Current expert reviews emphasize that TRIAC is the therapy farthest along for MCT8 deficiency; supplements do not replace it or other medical care.) Frontiers

---

Regenerative / stem-cell drugs

This condition is not an immune disease, and there are no approved stem-cell drugs for it. What follows are research and future-focused approaches; families should discuss clinical trials with their teams.

1. AAV9–SLC16A2 gene therapy (preclinical/early-stage research): delivers a working MCT8 gene via AAV9; in animal models, juvenile delivery improved brain T3 and motor/cognitive measures. Status: research; not standard care. bioRxiv+1

2. CNS-penetrant thyromimetics (sobetirome prodrug, Sob-AM2): designed to cross into the brain and mimic thyroid hormone without MCT8; in mouse and maternal-treatment studies, showed brain-targeted effects. Status: preclinical/experimental. PMC+1

3. Optimized TRIAC strategies (very early start): ongoing work asks if starting very early in life helps neurodevelopment more; data are still evolving and mixed. Status: clinical research. The Lancet+1

4. DITPA (diiodothyropropionic acid): older analog studied in small cohorts; biochemical effects reported; neurological impact uncertain. Status: investigational history; not standard. PMC

5. Prenatal maternal LT4 strategies (case-level reports): explored in selected families; outcomes vary; not established. Status: experimental, case-based. PMC

6. Future gene editing (CRISPR-based): conceptual at present; no human trials yet for MCT8 deficiency.

---

Surgeries and procedures

1. Gastrostomy tube (G-tube): for unsafe or insufficient oral feeding; improves nutrition, lowers aspiration risk.

2. Fundoplication (often with G-tube): for severe reflux with aspiration or discomfort despite maximum medical therapy.

3. Orthopedic tendon lengthening (e.g., Achilles/hamstrings): relieves fixed contractures to improve hygiene, positioning, and comfort.

4. Hip reconstruction or guided growth: for progressive hip subluxation/dislocation to reduce pain and facilitate sitting/care.

5. Spinal fusion for scoliosis (selected cases): to improve sitting balance, skin care, and comfort when curves are severe.

---

Preventions

1. Genetic counseling for families; offers carrier testing and reproductive options.

2. Early diagnosis using the thyroid “fingerprint” (T3/T4/rT3/TSH) to start care promptly.

3. Feeding safety: swallow management, reflux control, and positioning to prevent aspiration.

4. Vaccinations and respiratory hygiene to reduce infections.

5. Hip surveillance and contracture prevention programs.

6. Pressure sore prevention with proper seating and skin care.

7. Bone health: weight-bearing + vitamin D/calcium when needed.

8. Dental prevention: early and regular care, fluoride, suction training.

9. Seizure safety plans when relevant.

10. Caregiver training and respite to keep home care safe and sustainable. PMC

---

When to see a doctor (red flags)

• Any breathing trouble, choking, or suspected aspiration.

• Dehydration signs (very dry mouth, few wet diapers/urine).

• Rapid heartbeat, sweating, fever without cause, or unexplained weight loss.

• New or worsening seizures, unusual spells, or changes in awareness.

• Sudden increase in spasticity, pain, or loss of movement.

• Feeding refusal, vomiting, or poor weight gain.

• Back curvature or hip pain that makes sitting hard.

• Skin breakdown or sores.

• Any concern about over- or under-treatment while on TRIAC (fatigue, cold/warm intolerance, heart symptoms). (The modern guideline stress is to monitor thyroid state carefully.) PMC

---

What to eat and what to avoid

• Aim for energy-dense, easy-to-swallow foods (or formula) as advised by your dietitian; frequent small feeds help reflux.

• Plenty of fluids and fiber (as age-appropriate) to help constipation.

• Bone-supporting foods: dairy or fortified alternatives (for calcium), fish/eggs/fortified foods (for vitamin D), protein for growth.

• Avoid very high-iodine supplements or “thyroid boosters” marketed online—they can worsen hormone imbalance.

• Avoid choking hazards; use the liquid thickness your therapist recommends.

• Avoid unproven “cures” on the internet; discuss all supplements with the care team first.
  (These points align with the core treatment goal: support nutrition while managing peripheral thyrotoxicosis safely.) PMC

---

Frequently Asked Questions

1. What exactly is MCT8 deficiency?
   A genetic problem in the SLC16A2 gene that blocks thyroid hormone T3 from entering brain cells, causing brain hypothyroidism and body thyrotoxicosis. PMC

2. Why are T3 levels high but T4 low?
   The transporter problem and thyroid feedback lead to a signature profile: high T3, low T4, low rT3, TSH normal-mild high. PMC

3. How is it confirmed?
   By genetic testing of SLC16A2 plus the thyroid hormone pattern and clinical features. NCBI

4. Can newborn screening find it?
   Standard programs often miss it; low rT3 and high T3/rT3 ratio on dried blood spots show promise as add-on markers. PMC+1

5. Is there a medicine that treats the cause?
   No approved cure yet. TRIAC helps correct the peripheral hormone excess and is guideline-recommended; brain benefits are greatest when treatment starts very early, but results vary. PMC+1

6. Is TRIAC approved?
   In December 2024, the EMA recommended EU authorization for Emcitate (tiratricol) for peripheral thyrotoxicosis in MCT8 deficiency. Local availability can vary. European Medicines Agency (EMA)

7. What dose of TRIAC is used?
   Trials used weight-based or stepwise titration (for example, starting 175–350 μg/day and increasing to meet a target T3 range; median doses ~39 μg/kg/day). Dosing is individualized and needs expert monitoring. Oxford Academic+1

8. Does TRIAC enter the brain well?
   Data suggest limited brain penetration, so main benefits are peripheral; research on CNS-penetrant thyromimetics is ongoing. Cell+1

9. Are there curative options coming?
   AAV9 gene therapy has shown benefit in animal models; human trials are anticipated but not standard yet. bioRxiv

10. Can girls be affected?
    Most female carriers are asymptomatic; some can have symptoms if X-inactivation is skewed. NCBI

11. How is the heart protected?
    By controlling peripheral thyrotoxicosis (TRIAC) and using beta-blockers if needed under a doctor’s care. The Lancet

12. What does the MRI show?
    Often delayed myelination/hypomyelination. Frontiers

13. What specialists are involved?
    Endocrinology, neurology, genetics, physiatry, GI/nutrition, pulmonology/ENT, orthopedic surgery, and palliative/supportive care.

14. Can early treatment change outcomes?
    Early, coordinated care helps growth, comfort, and complications. Very early TRIAC may help more, but results are still being studied. ClinicalTrials.gov

15. Where can families find trusted information?
    GeneReviews, Orphanet, major children’s hospitals, and recent ETA/EMA communications and peer-reviewed reviews. NCBI+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 12, 2025.

PDF Documents For This Disease Condition References